Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (DEFINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04442737
Recruitment Status : Recruiting
First Posted : June 23, 2020
Last Update Posted : June 21, 2021
Sponsor:
Information provided by (Responsible Party):
Janssen Scientific Affairs, LLC

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 15, 2023
Estimated Study Completion Date : March 15, 2023